Philip W. Hinds

14.5k citations

107 papers · 11.8k indexed · 6 hit papers · h-index 47

Oncology top 0.1%
Molecular Biology top 0.5%
Cancer Research top 0.5%
Genetics top 1%
Biotechnology top 0.1%

Co-authors: Cathy A. Finlay Arnold J. Levine Robert A. Weinberg Andrew Arnold Steven I. Reed Steven F. Dowdy Daniel Eliyahu Moshe Oren
Topics: Cancer-related Molecular Pathways (61 papers)Ubiquitin and proteasome pathways (18 papers)Ocular Oncology and Treatments (16 papers)
Cited by: Oncology Biotechnology Cancer Research
Journals: Science Cell Proceedings of the National Academy of Sciences
Partner nations: United States Australia Japan

In The Last Decade

Philip W. Hinds

106 papers receiving 11.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The p53 proto-oncogene can act as a suppressor of transformation

1989 1.6k citations Cathy A. Finlay, Philip W. Hinds et al. profile →
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

1988 1.0k citations Cathy A. Finlay, Philip W. Hinds et al. Molecular and Cellular Biology profile →
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins

1992 899 citations Philip W. Hinds et al. profile →
Physical interaction of the retinoblastoma protein with human D cyclins

1993 666 citations Philip W. Hinds et al. profile →
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation

1989 499 citations Philip W. Hinds, Cathy A. Finlay et al. profile →
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

2000 442 citations Philip W. Hinds et al. profile →

Peers

Countries citing papers authored by Philip W. Hinds

Since Specialization

Citations

This map shows the geographic impact of Philip W. Hinds's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip W. Hinds with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip W. Hinds more than expected).

Fields of papers citing papers by Philip W. Hinds

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip W. Hinds. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip W. Hinds. The network helps show where Philip W. Hinds may publish in the future.

Co-authorship network of co-authors of Philip W. Hinds

This figure shows the co-authorship network connecting the top 25 collaborators of Philip W. Hinds. A scholar is included among the top collaborators of Philip W. Hinds based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip W. Hinds. Philip W. Hinds is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma 2024 ·American Journal Of Pathology ·Abraham Bayer,(unknown),Sasha Smolgovsky,Philip W. Hinds,Pilar Alcaide	2
2	A kinase-independent function of cyclin-dependent kinase 6 promotes outer radial glia expansion and neocortical folding 2022 ·Proceedings of the National Academy of Sciences ·(unknown),(unknown),Fengming Liu,(unknown),Shirui Hou,Jamy C. Peng,(unknown),(unknown),Yong‐Dong Wang,Hongjian Jin,Yiping Fan,Patrick J. Connelly,Shondra M. Pruett‐Miller,Miaofen G. Hu,Philip W. Hinds,Young-Goo Han	6
3	NDY1/KDM2B Functions as a Master Regulator of Polycomb Complexes and Controls Self-Renewal of Breast Cancer Stem Cells 2014 ·Cancer Research ·Filippos Kottakis,Parthena Foltopoulou,Ioannis Sanidas,Patricia J. Keller,Ania Wronski,Benjamin T. Dake,Scott A. Ezell,Zhu Shen,Stephen P. Naber,Philip W. Hinds,Elizabeth A. McNiel,Charlotte Kuperwasser,Philip N. Tsichlis	68
4	Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC 2013 ·Cancer Research ·Chi Luo,Jinghao Sheng,Miaofen G. Hu,Frank G. Haluska,Rutao Cui,Zhengping Xu,Philip N. Tsichlis,Guo‐fu Hu,Philip W. Hinds	25
5	Cyclin D1 Activity Regulates Autophagy and Senescence in the Mammary Epithelium 2012 ·Cancer Research ·Nelson E. Brown,Rinath Jeselsohn,Teeru Bihani,Miaofen G. Hu,Parthena Foltopoulou,Charlotte Kuperwasser,Philip W. Hinds	59
6	Overlapping and distinct pRb pathways in the mammalian auditory and vestibular organs 2011 ·Cell Cycle ·Mingqian Huang,Cyrille Sage,Yong Tang,(unknown),Marco Petrillo,Philip W. Hinds,Zheng‐Yi Chen	30
7	Cyclin D1 Kinase Activity Is Required for the Self-Renewal of Mammary Stem and Progenitor Cells that Are Targets of MMTV-ErbB2 Tumorigenesis 2010 ·Cancer Cell ·Rinath Jeselsohn,Nelson E. Brown,Lisa M. Arendt,Ina Klebba,Miaofen G. Hu,Charlotte Kuperwasser,Philip W. Hinds	105
8	A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis 2009 ·Cancer Research ·Miaofen G. Hu,Amit Deshpande,Miriam Enos,(unknown),(unknown),Guo‐fu Hu,Rui Chang,Zhuyan Guo,Marei Dose,Changchuin Mao,Philip N. Tsichlis,Fotini Gounari,Philip W. Hinds	96
9	A Role for the Cyclin Box in the Ubiquitin-Mediated Degradation of Cyclin G1 2008 ·Cancer Research ·Denise M. Piscopo,Philip W. Hinds	18
10	The retinoblastoma protein, RB, is required for gastrointestinal endocrine cells to exit the cell cycle, but not for hormone expression 2007 ·Developmental Biology ·Yang Wang,Subir K. Ray,Philip W. Hinds,Andrew B. Leiter	5
11	The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma 2006 ·Current Molecular Medicine ·Amit Deshpande,Philip W. Hinds	24
12	Proliferation of Functional Hair Cells in Vivo in the Absence of the Retinoblastoma Protein 2005 ·Science ·Cyrille Sage,Mingqian Huang,(unknown),Gabriel M. Gutierrez,Melissa A. Vollrath,(unknown),Jaime Garcı́a-Añoveros,Philip W. Hinds,Jeffrey T. Corwin,David P. Corey,Zheng‐Yi Chen	208
13	Master or slave: The complex relationship of RBP2 and pRb 2005 ·Cancer Cell ·Gabriel M. Gutierrez,(unknown),Philip W. Hinds	10
14	Cdk2 dethroned as master of S phase entry 2003 ·Cancer Cell ·Philip W. Hinds	29
15	Increased Ezrin Expression and Activation by CDK5 Coincident with Acquisition of the Senescent Phenotype 2003 ·Molecular Cell ·Hai-Su Yang,Philip W. Hinds	4
16	Aberrations in the MTS1 tumor suppressor locus in oral squamous cell carcinoma lines preferentially affect the INK4A gene and result in increased cdk6 activity 2002 ·Oral Oncology ·Siribang-on Piboonniyom,(unknown),Philip W. Hinds,Karl Münger	24
17	The Retinoblastoma Protein Acts as a Transcriptional Coactivator Required for Osteogenic Differentiation 2001 ·Molecular Cell ·David M. Thomas,Shannon A. Carty,Denise M. Piscopo,Jong-Seo Lee,(unknown),William C. Forrester,Philip W. Hinds	303
18	A yeast two-hybrid system for discerning differential interactions using multiple baits 1999 ·Nature Biotechnology ·Martha J. Grossel,(unknown),Bedrick B. Gadea,(unknown),Philip W. Hinds	14
19	Activating Mutations for Transformation by p53 Produce a Gene Product That Forms an hsc70-p53 Complex with an Altered Half-Life 1988 ·Molecular and Cellular Biology ·Cathy A. Finlay,Philip W. Hinds,Tse‐Hua Tan,Daniel Eliyahu,Moshe Oren,Arnold J. Levine	283
20	Delineation of Coding Areas in DNA Sequences Through Assignment of Codon Probabilities 1985 ·Journal of Biomolecular Structure and Dynamics ·Philip W. Hinds,R. D. Blake	14

About Philip W. Hinds

Philip W. Hinds is a scholar working on Oncology, Ophthalmology and Cell Biology, having authored 107 papers that have together received 11.8k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (61 papers), Ubiquitin and proteasome pathways (18 papers) and Ocular Oncology and Treatments (16 papers). The work is most often cited by research in Oncology (7.2k citations), Biotechnology (1.4k citations) and Cancer Research (2.0k citations). Philip W. Hinds has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Cathy A. Finlay, Arnold J. Levine, Robert A. Weinberg, Andrew Arnold, Steven I. Reed, Steven F. Dowdy, Daniel Eliyahu, Moshe Oren, Tse‐Hua Tan and Sibylle Mittnacht. Their work appears in journals such as Science, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact